Literature DB >> 8095320

Screening of children with hemihypertrophy, aniridia, and Beckwith-Wiedemann syndrome in patients with Wilms tumor: a report from the National Wilms Tumor Study.

D M Green1, N E Breslow, J B Beckwith, P Norkool.   

Abstract

To evaluate the usefulness of regular radiographic screening to detect an asymptomatic intraabdominal tumor in patients with an increased risk of developing Wilms tumor, we reviewed the files of patients with hemihypertrophy, aniridia, or Beckwith-Wiedemann syndrome who were registered on the National Wilms Tumor Studies. Screening was employed infrequently in the management of children with hemihypertrophy, with only 25% (6/24) of those whose hemihypertrophy was identified more than 30 days prior to the diagnosis of Wilms tumor undergoing such examinations. Most patients with aniridia were evaluated regularly for the occurrence of Wilms tumor. There were more stage 1 tumors identified in patients whose tumor was detected only through radiographic evaluation. The role of routine radiographic screening needs to be carefully evaluated in a homogeneous group of patients such as those with aniridia using a prospective study design to determine if such screening improves the survival rate of children with this rapidly growing, but readily treatable form of childhood cancer.

Entities:  

Mesh:

Year:  1993        PMID: 8095320     DOI: 10.1002/mpo.2950210307

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  11 in total

Review 1.  Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice.

Authors:  R H Scott; L Walker; Ø E Olsen; G Levitt; I Kenney; E Maher; C M Owens; K Pritchard-Jones; A Craft; N Rahman
Journal:  Arch Dis Child       Date:  2006-07-20       Impact factor: 3.791

2.  Hemihypertrophy, renal dysplasia and benign nephromegaly.

Authors:  Mohammad Amin Memon; Suravi Mohanty; Kanishka Das; Isha Garg; Ashley Lucien Joseph D'Cruz
Journal:  Pediatr Nephrol       Date:  2005-03-23       Impact factor: 3.714

Review 3.  Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour.

Authors:  R H Scott; C A Stiller; L Walker; N Rahman
Journal:  J Med Genet       Date:  2006-05-11       Impact factor: 6.318

Review 4.  Innovations in the management of Wilms' tumor.

Authors:  Joseph M Gleason; Armando J Lorenzo; Paul R Bowlin; Martin A Koyle
Journal:  Ther Adv Urol       Date:  2014-08

5.  Bilateral disease and new trends in Wilms tumour.

Authors:  Catherine M Owens; Hervé J Brisse; Øystein E Olsen; Joanna Begent; Anne M Smets
Journal:  Pediatr Radiol       Date:  2007-11-17

6.  The effectiveness of Wilms tumor screening in Beckwith-Wiedemann spectrum.

Authors:  Alessandro Mussa; Kelly A Duffy; Diana Carli; Jessica R Griff; Riccardo Fagiano; Jonida Kupa; Garrett M Brodeur; Giovanni Battista Ferrero; Jennifer M Kalish
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-04       Impact factor: 4.553

Review 7.  Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma.

Authors:  Jennifer M Kalish; Leslie Doros; Lee J Helman; Raoul C Hennekam; Roland P Kuiper; Saskia M Maas; Eamonn R Maher; Kim E Nichols; Sharon E Plon; Christopher C Porter; Surya Rednam; Kris Ann P Schultz; Lisa J States; Gail E Tomlinson; Kristin Zelley; Todd E Druley
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

Review 8.  Controversies and advances in the management of Wilms' tumour.

Authors:  K Pritchard-Jones
Journal:  Arch Dis Child       Date:  2002-09       Impact factor: 3.791

9.  Isolated hemihyperplasia in an infant: an overlooked sign for wilms tumor development.

Authors:  Kamer Mutafoglu; Emre Cecen; Handan Cakmakci
Journal:  Iran J Pediatr       Date:  2010-03       Impact factor: 0.364

10.  Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy.

Authors:  Arwa Nada; Jennifer G Jetton
Journal:  Pediatr Nephrol       Date:  2020-11-27       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.